Thermo Fisher Scientific Inc. has launched the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed system designed to help streamline formulation and filling in cell therapy manufacturing. 

Manufacturing workflows for cell therapies must accommodate variability in cell count, concentration and viability. As more therapies move toward commercialization, manufacturers look to reduce manual intervention and improve operational efficiency while maintaining strict requirements for sterility, dose accuracy and product consistency. 

Formulation and filling have been traditionally performed using manual methods that require careful handling of fragile cells in small volumes, introducing variability and risk of contamination. The CTS Compleo system offers a compact, automated, functionally closed solution for formulation and filling, helping reduce manual intervention and supporting consistent batch-to-batch performance, according to the company.

“We’re excited to bring forward a solution that addresses one of the biggest bottlenecks in cell therapy manufacturing, manual fill and finish,” said Tiffani Manolis, vice president and general manager, cell biology, Thermo Fisher Scientific. “By combining automation with a functionally closed design, the Gibco CTS Compleo system has the ability to streamline workflows, improve consistency, and help customers accelerate the delivery of life-changing therapies to patients.”  

The CTS Compleo system is part of the Gibco Cell Therapy Systems (CTS) portfolio designed to support cell therapy manufacturers with instruments, consumables and software, GMP-manufactured media and reagents, and viral vector systems. Together, these solutions, along with our Gibco PeproGMP growth factors and cytokines, are designed to help enable GMP-compliant, closed-system manufacturing and allow for physical and digital integration across the workflow.